No specific molecular target – effects mediated via broad paracrine secretion of multiple factors (N/A)

This entry describes a therapeutic mechanism rather than a single molecular entity, typically associated with cell-based therapies such as Mesenchymal Stem Cells (MSCs). MSCs are often referred to as 'Medicinal Signaling Cells' because their primary therapeutic effect is not through direct differentiation into host tissue, but through the secretion of a diverse array of bioactive molecules, including cytokines, growth factors, and extracellular vesicles (exosomes) (Caplan, 2017, Stem Cells Transl Med). This 'secretome' exerts broad paracrine effects that modulate the immune system, promote angiogenesis, and stimulate endogenous repair mechanisms in the target tissue (Galipeau & Sensébé, 2018, Cell Stem Cell). Because the clinical outcome depends on the synergistic action of multiple factors (e.g., PGE2, IDO, TGF-beta, VEGF), there is no single molecular target that can be isolated as the sole driver of efficacy (Vizoso et al., 2017, Int J Mol Sci). This approach is utilized in treating complex conditions like Graft-versus-Host Disease (GvHD) and Crohn's disease, where multi-pathway modulation is required to achieve a therapeutic response.

Other names

Paracrine signaling mechanismSecretome-mediated effectBystander effectMSC-mediated paracrine actionMedicinal signaling mechanism

Therapeutic effects are achieved through the collective secretion of a diverse array of cytokines, growth factors, and extracellular vesicles (exosomes) that modulate the local microenvironment and stimulate endogenous repair processes.